An immunotherapy clinical trial based in Seattle, among other U.S. sites, was pivotal to the Dec.
Frisco, Texas, resident Steve Murphy, 66, was diagnosed last September with Merkel cell carcinoma, a rare skin cancer he’d never heard of. His grim prognosis: 50 percent chance of surviving 90 days.
The number of U.S. cases of Merkel cell carcinoma, an often-fatal skin cancer, is rising about six times faster than most other cancers and at nearly twice the rate of the more-common melanoma.
One in eight women in the United States is diagnosed with breast cancer. For women who survive, there’s always concern about the cancer coming back. Scientists at UW Medicine in Seattle are developing a new vaccine to try to stop such recurrenc
Many patients with advanced Merkel cell carcinoma who received the immunotherapeutic pembrolizumab as first-line therapy in a